Debra Maude
Acute Care · Pennington, NJNPI 1912280165
Payments from drug & device makers
Across 49 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$255
- Astellas Pharma US Inc$110
- Gilead$103
- Lilly USA, LLC$88
- Eisai Inc.$88
- Johnson & Johnson$83
- plus $503 from 17 others
What the payments were for
- Food & beverage$79164%
- Education$43836%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 3 | $255 |
| Astellas Pharma US Inc | 2 | $110 |
| Gilead | 2 | $103 |
| Lilly USA, LLC | 6 | $88 |
| Eisai Inc. | 4 | $88 |
| Johnson & Johnson(2 entities) | 5 | $83 |
| Sobi, Inc | 3 | $55 |
| Taiho Oncology, Inc. | 3 | $53 |
| AstraZeneca | 3 | $46 |
| Stemline Therapeutics Inc. | 2 | $42 |
| Merck | 2 | $42 |
| GSK | 2 | $34 |
| Pharmaessentia USA Corporation | 2 | $32 |
| Emmaus Medical, Inc. | 1 | $30 |
| Novartis | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Sanofi | 1 | $15 |
| Servier Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,229 in reported general payments places this provider in the 75th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 28 | $47,398 |
| Oxycodone Hcl | 177 | $4,250 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 60 | $1,068 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $605 |
| Prochlorperazine Maleate | 28 | $573 |
| Lorazepam | 45 | $344 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 15 | $256 |
| Ondansetron OdtOndansetron | 11 | $186 |
| Zolpidem Tartrate | 21 | $173 |
| Tramadol Hcl | 17 | $89 |
| Alprazolam | 18 | $63 |
| Venlafaxine Hcl | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other acute care in Pennington
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Hanane ChaibainouWestampton$16K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
- Vincent FroncekFlemington$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.